Conferences

ecancer travels so that you don't have to. Expore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

ASH 2016

3 - 6 Dec 2016
San Diego, United States of America
ASH 2016: Multiple myeloma highlights
Prof Marivi Mateos, Prof Philippe Moreau, Prof Saad Usmani, Prof Heinz Ludwig
ASH 2016: Multiple myeloma highlights ( Prof Marivi Mateos, Prof Philippe Moreau, Prof Saad Usmani, Prof Heinz Ludwig )
6 Dec 2016
Interim results from the ZUMA-1 trial of novel CAR-T cells against non-Hodgkin l...
Dr Sattva Neelapu - MD Anderson Cancer Center, Houston, USA
Interim results from the ZUMA-1 trial of novel CAR-T cells against non-Hodgkin lymphoma ( Dr Sattva Neelapu - MD Anderson Cancer Center, Houston, USA )
6 Dec 2016
Pacritinib versus best available therapy for low platelet Myelofibrosis
Dr John Mascarenhas - Mount Sinai School of Medicine New York, USA
Pacritinib versus best available therapy for low platelet Myelofibrosis ( Dr John Mascarenhas - Mount Sinai School of Medicine New York, USA )
6 Dec 2016
Dose escalation of CPI-613 with bendamustine for relapsed T Cell NHL
Dr Zanetta Lamar - Wake Forest Baptist Medical Center, Winston-Salem, USA
Dose escalation of CPI-613 with bendamustine for relapsed T Cell NHL ( Dr Zanetta Lamar - Wake Forest Baptist Medical Center, Winston-Salem, USA )
6 Dec 2016
DVd vs Vd for relapsed or refractory myeloma: CASTOR trial update
Prof Marivi Mateos - University Hospital of Salamanca, Salamanca, Spain
DVd vs Vd for relapsed or refractory myeloma: CASTOR trial update ( Prof Marivi Mateos - University Hospital of Salamanca, Salamanca, Spain )
6 Dec 2016
ASH 2016 highlights: breaking new ground in haematology
Dr Giovanni Martinelli - Università di Bologna, Bologna, Italy
ASH 2016 highlights: breaking new ground in haematology ( Dr Giovanni Martinelli - Università di Bologna, Bologna, Italy )
6 Dec 2016
TCA cycle inhibition by CPI-613 increases chemo sensitivity in older AML patient...
Dr Timothy Pardee - Wake Forest Baptist Medical Center, Winston-Salem, USA
TCA cycle inhibition by CPI-613 increases chemo sensitivity in older AML patients ( Dr Timothy Pardee - Wake Forest Baptist Medical Center, Winston-Salem, USA )
6 Dec 2016
Azacitidine plus nivolumab against acute myeloid leukaemia
Prof Naval Daver - MD Anderson Cancer Center, Houston, USA
Azacitidine plus nivolumab against acute myeloid leukaemia ( Prof Naval Daver - MD Anderson Cancer Center, Houston, USA )
6 Dec 2016
IKZF1 mutations associated with paediatric ALL
Dr Michelle Churchman - St. Jude Children's Research Hospital, Memphis, USA
IKZF1 mutations associated with paediatric ALL ( Dr Michelle Churchman - St. Jude Children's Research Hospital, Memphis, USA )
5 Dec 2016
Rituximab after ASCT prolongs survival for young MCL patients
Prof Steven Le Gouill - Nantes Medical University, Nantes, France
Rituximab after ASCT prolongs survival for young MCL patients ( Prof Steven Le Gouill - Nantes Medical University, Nantes, France )
5 Dec 2016
How can we use crenolanib to treat AML?
Dr Eunice Wang - Roswell Park Cancer Institute, New York, USA
How can we use crenolanib to treat AML? ( Dr Eunice Wang - Roswell Park Cancer Institute, New York, USA )
5 Dec 2016
Highlights in myeloid leukaemia research from ASH 2016
Dr Luca Mazzarella - European Institute of Oncology, Milan, Italy
Highlights in myeloid leukaemia research from ASH 2016 ( Dr Luca Mazzarella - European Institute of Oncology, Milan, Italy )
5 Dec 2016
Thromboembolytic risks of central venous catheters in paediatric patients
Dr Julie Jaffray - Children's Center for Cancer, Los Angeles, USA
Thromboembolytic risks of central venous catheters in paediatric patients ( Dr Julie Jaffray - Children's Center for Cancer, Los Angeles, USA )
5 Dec 2016
Pure erythroid leukaemias
Dr Guillermo Montalbán Bravo - MD Anderson Cancer Center, Houston, USA
Pure erythroid leukaemias ( Dr Guillermo Montalbán Bravo - MD Anderson Cancer Center, Houston, USA )
5 Dec 2016
Clinical updates for guadecitabine and vorinostat
Dr Guillermo Montalbán Bravo - MD Anderson Cancer Center, Houston, USA
Clinical updates for guadecitabine and vorinostat ( Dr Guillermo Montalbán Bravo - MD Anderson Cancer Center, Houston, USA )
5 Dec 2016
ALL: Combining paediatric-type therapy with minimal residual disease
Dr Alessandro Rambaldi - Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy
ALL: Combining paediatric-type therapy with minimal residual disease ( Dr Alessandro Rambaldi - Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy )
5 Dec 2016
Pracinostat and azacitidine for elderly AML
Prof Guillermo Garcia-Manero - MD Anderson Cancer Center, Houston, USA
Pracinostat and azacitidine for elderly AML ( Prof Guillermo Garcia-Manero - MD Anderson Cancer Center, Houston, USA )
5 Dec 2016
ASH 2016: AML, CLL and leukaemogenesis latest
Dr Farhad Ravandi - MD Anderson Cancer Center, Houston, USA
ASH 2016: AML, CLL and leukaemogenesis latest ( Dr Farhad Ravandi - MD Anderson Cancer Center, Houston, USA )
5 Dec 2016
Advances in CLL from ASH 2016
Prof Stephan Stilgenbauer, Prof Clemens-Martin Wendtner, Prof Steven Coutre And ...
Advances in CLL from ASH 2016 ( Prof Stephan Stilgenbauer, Prof Clemens-Martin Wendtner, Prof Steven Coutre And Dr Jeffery Jones )
5 Dec 2016
Ineligibility required for 'anti-trials': inclusion in studies regardless of fit...
Prof Guillermo Garcia-Manero - MD Anderson Cancer Center, Houston, USA
Ineligibility required for 'anti-trials': inclusion in studies regardless of fitness ( Prof Guillermo Garcia-Manero - MD Anderson Cancer Center, Houston, USA )
5 Dec 2016
Vosaroxin for relapsed AML: Updates from VALOR
Dr Farhad Ravandi - MD Anderson Cancer Center, Houston, USA
Vosaroxin for relapsed AML: Updates from VALOR ( Dr Farhad Ravandi - MD Anderson Cancer Center, Houston, USA )
5 Dec 2016
Impact of next-generation sequencing on treatment choice for MDS
Dr Ana Alfonso Pierola - MD Anderson Cancer Center, Houston, USA
Impact of next-generation sequencing on treatment choice for MDS ( Dr Ana Alfonso Pierola - MD Anderson Cancer Center, Houston, USA )
4 Dec 2016
Obinutuzumab extends PFS for follicular lymphoma in GALLIUM trial
Dr Andrew Davies - University of Southampton, Southampton, UK
Obinutuzumab extends PFS for follicular lymphoma in GALLIUM trial ( Dr Andrew Davies - University of Southampton, Southampton, UK )
4 Dec 2016
Venetoclax plus cytarabine in elderly AML patients
Dr Andrew Wei - Alfred Hospital, Melbourne, Australia
Venetoclax plus cytarabine in elderly AML patients ( Dr Andrew Wei - Alfred Hospital, Melbourne, Australia )
4 Dec 2016
Intravenous or subcutaenous rituximab for FL in the SABRINA study
Dr Andrew Davies - University of Southampton, Southampton, UK
Intravenous or subcutaenous rituximab for FL in the SABRINA study ( Dr Andrew Davies - University of Southampton, Southampton, UK )
4 Dec 2016
Ibrutinib in CLL: RESONATE and resistance
Dr Jennifer Woyach - The Ohio State University Medical Center, Columbus, USA
Ibrutinib in CLL: RESONATE and resistance ( Dr Jennifer Woyach - The Ohio State University Medical Center, Columbus, USA )
4 Dec 2016
Large granular lymphocyte proliferations in MDS
Dr Christa Roe - H. Lee Moffitt Cancer Center, Tampa, USA
Large granular lymphocyte proliferations in MDS ( Dr Christa Roe - H. Lee Moffitt Cancer Center, Tampa, USA )
4 Dec 2016
Durable remissions with the VcR-CVAD regimen for MCL regardless of age
Dr Julie Chang - University of Wisconsin Hospital and Clinics, Madison, USA
Durable remissions with the VcR-CVAD regimen for MCL regardless of age ( Dr Julie Chang - University of Wisconsin Hospital and Clinics, Madison, USA )
4 Dec 2016
TKI cessation for CML patients with deep molecular response: an update from the ...
Dr Francois-Xavier Mahon - Université Bordeaux, Bordeaux, France
TKI cessation for CML patients with deep molecular response: an update from the EURO-SKI trial ( Dr Francois-Xavier Mahon - Université Bordeaux, Bordeaux, France )
3 Dec 2016
Tailoring therapy for leukaemia patients
Dr Mikkael Sekeres - Cleveland Clinic, Cleveland, USA
Tailoring therapy for leukaemia patients ( Dr Mikkael Sekeres - Cleveland Clinic, Cleveland, USA )
3 Dec 2016
Dose reduction of TKIs for CML patients with deep molecular response
Prof Mhairi Copland - University of Glasgow, Glasgow, UK
Dose reduction of TKIs for CML patients with deep molecular response ( Prof Mhairi Copland - University of Glasgow, Glasgow, UK )
3 Dec 2016
Updates from the EURO-SKI trial of tyrosine kinase cessation
Dr Francois-Xavier Mahon - Université Bordeaux, Bordeaux, France
Updates from the EURO-SKI trial of tyrosine kinase cessation ( Dr Francois-Xavier Mahon - Université Bordeaux, Bordeaux, France )
3 Dec 2016
Incidence and risk factors for central venous catheter related thrombosis in chi...
Dr Julie Jaffray - Children's Center for Cancer, Los Angeles, USA
Incidence and risk factors for central venous catheter related thrombosis in children ( Dr Julie Jaffray - Children's Center for Cancer, Los Angeles, USA )
3 Dec 2016
CML patients with stable response may safely decrease dose of TKI
Prof Mhairi Copland - University of Glasgow, Glasgow, UK
CML patients with stable response may safely decrease dose of TKI ( Prof Mhairi Copland - University of Glasgow, Glasgow, UK )
3 Dec 2016
Vadastuximab talirine in combination for newly diagnosed AML
Prof Harry Erba - UAB Comprehensive Cancer Center, Birmingham, USA
Vadastuximab talirine in combination for newly diagnosed AML ( Prof Harry Erba - UAB Comprehensive Cancer Center, Birmingham, USA )
3 Dec 2016
Novel antibody boosts responses in newly diagnosed AML
Prof Harry Erba - UAB Comprehensive Cancer Center, Birmingham, USA
Novel antibody boosts responses in newly diagnosed AML ( Prof Harry Erba - UAB Comprehensive Cancer Center, Birmingham, USA )
3 Dec 2016
Anti CD22 CAR T cell therapy for relapsed paediatric ALL
Dr Nirali Shah - National Cancer Institute, Bethesda, USA
Anti CD22 CAR T cell therapy for relapsed paediatric ALL ( Dr Nirali Shah - National Cancer Institute, Bethesda, USA )
3 Dec 2016
A new spin on leukaemia therapy
Prof Armand Keating - University of Toronto, Toronto, Canada
A new spin on leukaemia therapy ( Prof Armand Keating - University of Toronto, Toronto, Canada )
3 Dec 2016
Subgroup analysis of elderly high risk AML patients receiving CPX-351
Prof Jeffery Lancet - H. Lee Moffitt Cancer Center, Tampa, USA
Subgroup analysis of elderly high risk AML patients receiving CPX-351 ( Prof Jeffery Lancet - H. Lee Moffitt Cancer Center, Tampa, USA )
3 Dec 2016
Remissions following anti-CD22 CAR therapy in children with relapsed ALL
Dr Terry Fry - National Cancer Institute, Bethesda, USA
Remissions following anti-CD22 CAR therapy in children with relapsed ALL ( Dr Terry Fry - National Cancer Institute, Bethesda, USA )
3 Dec 2016
CPX-351 after stem cell transplant for elderly patients with AML
Prof Jeffery Lancet - H. Lee Moffitt Cancer Center, Tampa, USA
CPX-351 after stem cell transplant for elderly patients with AML ( Prof Jeffery Lancet - H. Lee Moffitt Cancer Center, Tampa, USA )
3 Dec 2016